EARAD v1.0

  • Research type

    Research Study

  • Full title

    The Effects on Auditory Function of Radiotherapy and Chemotherapy Treatments for Head and Neck Tumours

  • IRAS ID

    247959

  • Contact name

    Chris Plack

  • Contact email

    chris.plack@manchester.ac.uk

  • Sponsor organisation

    The University of Manchester

  • Duration of Study in the UK

    2 years, 11 months, 31 days

  • Research summary

    Many head and neck cancers are treated by radiotherapy (using intense radiation to destroy the tumour) alone or with chemotherapy (using chemicals to destroy the tumour). When radiotherapy is used to treat a cancer, the patient undergoes imaging to identify the tumour and surrounding healthy organs such as the cochlea in the inner ear. The radiotherapy is then planned so that the radiation beam is shaped to maximise the dose to the tumour and minimise the dose to the nearby healthy tissue. It is known that radiation can damage the sensitive structures in the inner ear, and possibly also hearing functions in the brain. This project aims to: (1) understand and measure hearing deficits after cancer therapy; (2) find the hearing substructures most sensitive to radiotherapy; and (3) provide the basis for optimising radiotherapy for future patients to strike the best balance between tumour control and hearing preservation.
    We will use a sensitive range of tests, including listening tests and measures of the electrical activity of neurons, to assess hearing function in patients before and after radiotherapy, with and without chemotherapy, for tumours in the head and neck region. We will also determine the impact of any real-world problems, particularly listening to speech in noise. State-of-the-art computational techniques will be used to link the radiotherapy dose delivered to hearing regions close to the tumour area with the various aspects of hearing loss.
    With the collected knowledge, we will provide the basis for guidelines to specifically spare those regions in the hearing pathway that are most sensitive to radiotherapy (without compromising the coverage for the cancer), and minimise long-term hearing damage.

  • REC name

    North West - Greater Manchester Central Research Ethics Committee

  • REC reference

    18/NW/0681

  • Date of REC Opinion

    17 Oct 2018

  • REC opinion

    Favourable Opinion